Therapy-Related Myeloid Neoplasms in Patients Treated for Hodgkin Lymphoma

Por Eichenauer, D.A., Engert, A.
Publicado em 2011

Compatible-Solute-Supported Periplasmic Expression of Functional Recombinant Proteins under Stress Conditions

Por Barth, S., Huhn, M., Matthey, B., Klimka, A., Galinski, E. A., Engert, A.
Publicado em 2000

A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin

Por CASTELLETTI, D, FRACASSO, G, RIGHETTI, S, TRIDENTE, G, SCHNELL, R, ENGERT, A, COLOMBATTI, M
Publicado em 2004

Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning

Por Klimka, A, Matthey, B, Roovers, R C, Barth, S, Arends, J-W, Engert, A, Hoogenboom, H R
Publicado em 2000

First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation

Por Wilhelm, M, Smetak, M, Reimer, P, Geissinger, E, Ruediger, T, Metzner, B, Schmitz, N, Engert, A, Schaefer-Eckart, K, Birkmann, J
Publicado no Blood Cancer J (2016)

An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETÁ) is a potent immunotoxin against a Hodgkin-derived cell line

Por Klimka, A, Barth, S, Matthey, B, Roovers, R C, Lemke, H, Hansen, H, Arends, J-W, Diehl, V, Hoogenboom, H R, Engert, A
Publicado em 1999

Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies

Por Han, T. H., Chen, R., Advani, R., Berryman, R. B., Smith, S. E., Forero-Torres, A., Rosenblatt, J. D., Smith, M. R., Zain, J., Hunder, N. N., Engert, A.
Publicado em 2013

Sexual quality of life in Hodgkin Lymphoma: a longitudinal analysis by the German Hodgkin Study Group

Por Behringer, K, Müller, H, Görgen, H, Flechtner, H-H, Brillant, C, Halbsguth, T V, Thielen, I, Eichenauer, D A, Schober, T, Nisters-Backes, H, Fuchs, M, Engert, A, Borchmann, P
Publicado em 2013

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

Por Younes, A., Hilden, P., Coiffier, B., Hagenbeek, A., Salles, G., Wilson, W., Seymour, J. F., Kelly, K., Gribben, J., Pfreunschuh, M., Morschhauser, F., Schoder, H., Zelenetz, A. D., Rademaker, J., Advani, R., Valente, N., Fortpied, C., Witzig, T. E., Sehn, L. H., Engert, A., Fisher, R. I., Zinzani, P.-L., Federico, M., Hutchings, M., Bollard, C., Trneny, M., Elsayed, Y. A., Tobinai, K., Abramson, J. S., Fowler, N., Goy, A., Smith, M., Ansell, S., Kuruvilla, J., Dreyling, M., Thieblemont, C., Little, R. F., Aurer, I., Van Oers, M. H. J., Takeshita, K., Gopal, A., Rule, S., de Vos, S., Kloos, I., Kaminski, M. S., Meignan, M., Schwartz, L. H., Leonard, J. P., Schuster, S. J., Seshan, V. E.
Publicado no Ann Oncol (2017)